Introduction
Forty-one years since its clinical introduction, valproate has become the most widely prescribed antiepileptic drug (AED) worldwide. 1 The pharmacological effects of valproate involve a variety of mechanisms, including increased g-aminobutyric acid (GABA)-ergic transmission, reduced release and/or effects of excitatory amino acids, blockade of voltage-gated sodium channels, and modulation of dopaminergic and serotonergic transmission.
Valproate is a broad spectrum AED, being effective against all seizure types, and is available in different dosage forms for parenteral and oral use. 1 All oral formulations are almost completely bioavailable, although they differ in dissolution characteristics and absorption rates. In particular, extendedrelease (ER) formulations are available that minimize fluctuations in serum drug concentrations during a dosing interval, and can therefore be given once or twice daily. 2 However, there are limited data evaluating the efficacy and tolerability of the ER formulation of valproate, especially in mainland China. As such, we conducted a prospective and multicentre trial with the aim of assessing the efficacy, safety profiles, and quality of life (QOL) issues associated with the ER formulation of valproate in China.
Methods

Study design
The present study was conducted in 21 centres across mainland China. Neurologists at every study site identified eligible patients. Clinicians were asked to identify seizures and epilepsy syndromes by International League Against Epilepsy classifications 3, 4 as far as was possible. After enrolment, patients were prescribed the ER formulation of valproate (Deparkine Chrono) as initial or add-on therapy. The rate of titration, initial and maintenance dose, and any subsequent increments or decrements were decided by the clinician according to their everyday practice. The aim of treatment was to control seizures with a minimum effective dose of drug, which necessitated dose increments if further seizures took place. Information recorded at study entry (V0) included patient demographics, seizure onset age, seizure frequency, and AEDs
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therapy. Efficacy and safety re-evaluation procedures were performed at 1 (V1), 3 (V2), and 6 months (V3) after enrolment. A QOLIE-31 inventory was used to assess the QOL before and after the 6-month treatment. The patients taking conventional valproate were directly replaced by the ER formulation at baseline. Any other concomitant AEDs were not allowed to be adjusted or added during the whole study period. The studies were conducted in accordance with the International Conference on Harmonization Notes for Guidance on Good Clinical Practice and the Declaration of Helsinki. The relevant study protocol was approved by an independent Ethics Committee or Institutional Review Board at each study centre. All patients (or a parent or legal guardian) provided written informed consent and all minors signed a consent form.
Study population
Patients were eligible for the study if they were 6-65 years of age, were diagnosed with epilepsy, experienced at least one seizure attack in the last 3 months before baseline visit, with any seizure type classifiable by the International Classification of Seizures, and, if female, had a negative urine or serum pregnancy test at screening and agreed to use acceptable contraceptive methods during the study or were incapable of bearing children. Patients were excluded from the study for using more than two AEDs or ER valproate, use of any investigational drug within the previous 12 weeks, chronic use of any medication that could influence seizure control, any acute or progressive neurological or severe psychiatric disease, and any medical condition associated with significant changes in body weight.
Efficacy assessment
Throughout the study, each patient (or a parent or legal guardian) recorded the date, number, and type of seizures experienced on a daily record card which was reviewed by an investigator at each study visit. Baseline seizure frequency was calculated from the 3-month retrospective baseline. The efficacy endpoints included percent change in seizure frequency of any type per month from baseline over the treatment period, proportion of patients with !50% reduction from baseline in seizure frequency per month (!50% responder rate) during the treatment period, and the seizure freedom rate during the evaluation period. Only patients who completed the entire evaluation period without experiencing any type of seizure were considered to be seizure free, while any patient who discontinued study medication prematurely was regarded as not seizure free.
Safety assessment
Safety was determined by assessment of adverse events, monitoring of vital signs, and physical and neurological examinations. Details recorded included intensity (mild, moderate, and severe) and the relationship to study medication, as judged by the investigator.
Quality of life assessment
For patients at least 18 years of age, health-related QOL was measured in the clinic using the Quality of Life in Epilepsy Inventory (QOLIE-31), a widely used instrument developed especially for the evaluation of QOL in adult patients with epilepsy, and one that has been extensively tested for validity and reliability. 5, 6 QOLIE-31 consists of 31 questions divided into seven domains: emotional well-being, social functioning, energy/fatigue, cognitive functioning, seizure worry, medication effects, and overall QOL. Each domain was scored by calculating the mean score of the responses to the questions within that domain. Question 31 is a subjective self-assessment of the subjects' general health condition and was not included in the seven domains. QOLIE-31 scores at baseline and at the end of the 6-month treatment period were computed for each sub-scale according to the developers' instructions. Higher scores reflect better QOL, while lower ones reflect worse QOL.
Statistical methods
Descriptive statistics were calculated for all outcome variables, and are expressed as mean AE SD or medians and ranges as appropriate. The percent reduction from baseline in seizure frequency per month was compared using the Wilcoxon signed rank-sum test. A !50% responder, seizure freedom rates, and treatment-emergent adverse events were summarized using descriptive statistics. Paired T-test was used to examine the change of each item score in QOLIE-31 before and after treatment. All data were analyzed with statistical analysis software SPSS 13.0. Differences with a P value <0.05 were considered significant.
Results
Patients sample
Nine hundred and fifty-eight patients (mean age 17.6 years, range 6-65 years) with diagnosis of epilepsy were included in the analysis. There were 61.6% males and 38.4% females. The main characteristics of patients can be seen in Table 1 . ER valproate was discontinued in 112 patients (11.7%) secondary to uncontrolled seizure and adverse events.
Dosage of study drug and efficacy
The median dose of ER valproate was 500 mg/d (range 125-2000 mg/d) at V0 and was increased to 750 mg/d (range 125-2000 mg/d) at the following visits. The median (25, 75 percentiles) of seizure counts per month was significantly decreased (P = 0.000) at every follow-up visit when compared with the previous visit ( Table 2 ). The results of efficacy analysis in the population of patients treated with other AEDs and still having seizure (N = 297) and in the population of newly diagnosed patients (N = 549) were consistent with those in all subjects as a whole, and there was no significantly difference between two groups (P > 0.05). During the 6-month treatment period the median percent reduction from baseline in seizures per month for all seizure types was 88.3%. Overall, 90.1% of patients on ER valproate therapy had at least a 50% seizure reduction (good responders), and 50.5% remained seizure free (Fig. 1) . According to epilepsy type, there was no difference in seizure control with ER valproate treatment between generalized and focal epilepsy. However, the median dose of ER valproate at the maintenance phase was significant higher (P < 0.05) in patients with focal epilepsy (1000 mg/d) than in those with generalized epilepsy (750 mg/d), but with the same efficacy.
Safety
Adverse effects that were considered to be related to study treatment at the first month visit occurred in 9.2% of patients, with increased appetite, dizziness, nausea, vomiting, and declined cognition most commonly reported. Complaints of increased body weight, hair loss, hand tremor, and drowsiness were reported 6.7% of patients after the 6-month treatment. Seven (0.7%) patients were withdrawn from the study because of adverse effects.
Quality of Life
A total of 407 adult patients finished QOLIE-31 for the evaluation of QOL at baseline and after the 6-month treatment. A summary and comparison of the scores for each domain can be seen in Table 3 . At the end of the 6-month treatment, patient's experienced significant QOL improvements on the seizure worry (P = 0.000), overall QOL (P = 0.000), social functioning (P < 0.01), and Question 31 (P = 0.000) domains of the QOLIE-31, while the energy/fatigue domain was significantly decreased (P = 0.000).
Discussion
Valproate is a broad spectrum AED, being effective against all seizure types. In an early review of 41 mostly non-comparative trials using valproate of varying duration 7 efficacy rates, defined as the percentage of patients showing a >75% reduction in seizure frequency compared with baseline, indicated that valproate, used mostly as adjunctive therapy, was effective in 61% of patients overall, with the response usually greater in patients with generalized seizures compared with those with partial seizures. The UK adult EPITEG trial evaluated 300 patients with newly diagnosed, previously untreated epilepsy, of whom approximately one-half had partial seizures and the remaining were diagnosed as having primarily generalized tonic-clonic seizures. 8 After 3 years of follow-up, valproate and carbamazepine were found to be equally efficacious, irrespective of seizure type. The adverse effects profiles of valproate have been evaluated in clinical studies and in extensive postmarketing reports. [9] [10] [11] Of the dose-dependent adverse effects, gastrointestinal disturbances such as nausea, vomiting, and indigestion, and more rarely diarrhoea, abdominal cramps, and constipation, were more common at initiation of treatment; those effects, however, are usually transient and do not generally require discontinuation of treatment. 9, 12 Adverse CNS effects are less common with valproate than with other AEDs. In the adult EPITEG trial, 6% of patients assigned to valproate developed tremor, compared with 2% of patients allocated to carbamazepine. 8 Less common adverse CNS effects of valproate include headache, nystagmus, dizziness, diplopia, amblyopia, blurred vision, incoordination, parkinsonian symptoms, and behavioural or psychiatric disorders. 10, 13 One significant adverse effect during long-term treatment with valproate is the potential for bodyweight gain 14 and in the EPITEG trial the incidence of bodyweight gain during valproate treatment was 15%. 8 Valproate is a major antiepileptic drug with a wide spectrum of activity and low toxicity. In patients on long-term therapy, plasma valproate levels fluctuate extensively within each dosing interval due to the drug's small distribution volume, rapid absorption, and short half-life. To reduce the diurnal variation in plasma valproate concentrations and to improve compliance with drug intake, ER valproate preparations, given less frequently, are often substituted from rapidly absorbed preparations. The ER valproate has different pharmacokinetic profiles from conventional valproate, including a delayed peak time and a reduced peak concentration. 15 ER valproate may also be useful for the prevention of valproateinduced hepatotoxicity, the risk for which was enhanced with high valproate concentrations. 16 Smaller diurnal fluctuations in valproate concentrations during treatment with the ER formulation were shown to result in lowered concentrations of minor metabolites including 4-en-valproate, the most toxic metabolite. 17 The results of the present study demonstrated that patients receiving ER valproate as initial or add-on therapy for 6 months resulted in 88.3% reduction of seizure frequency from baseline for all seizure types, and high responder rates and seizure freedom rates (50.5%), while 6.7-9.2% of patients reported adverse effects during the different phases of the study. Our results also suggested that the dose of ER valproate used in patients with partial seizures was significantly higher than in patients with generalized seizure in order to gain the same efficacy. These findings are generally consistent with previous studies, although our adverse effects rate was lower, mainly due to the favourable pharmaceutical characteristics of the ER valproate. Although remission of seizures has been found to be associated with improvements in health-related QOL, the impact of partial reductions in seizure frequency is more ambiguous. These considerations highlight the importance of measuring healthrelated QOL in clinical trials of antiepileptic drug therapy. The results from the present study demonstrated improvements in some aspects of health-related QOL as measured with the QOLIE-31 after a 6-month treatment with ER valproate. Previous studies have suggested that the QOL improvements occurring independently of changes in seizure frequency may arise from factors such as reduction in seizure severity or the positive psychotropic or mood-stabilizing effects of antiepileptic drugs. 13, 16 Our data corroborate previous observations of enhanced mood, social interaction, and general well-being in patients with epilepsy treated with valproate. 18 Valproate has also been established as an effective mood stabilizer in bipolar disorder in case series, openlabel studies, and double-blind, placebo-controlled trials.
A limitation of the present study was its non-randomized, nonblind, and non-control design. To compensate for this shortcoming, we recruited 958 patients and achieved a high level of completeness of follow-up in order to increase the precision and confidence in the results.
Patients with epilepsy receiving ER valproate as add-on or mono-therapy for 6 months resulted in significant reductions from baseline in seizure frequency for all seizure types, and high responder rates and seizure freedom rates. The dose of ER valproate used in patients with partial seizures was significantly higher than in patients with generalized seizure in order to gain the same efficacy. Patients with epilepsy in this study demonstrated good tolerance and improved quality of life with 6-month treatment of ER valproate.
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